Altimmune Inc - ALT Company Long-Term Liabilities

Public company logo of Altimmune Inc (ALT)

Altimmune, Inc. (ALT) develops innovative treatments to combat obesity and diabetes. This chart on GURU.Markets captures the 0.04 metric. Altimmune, Inc. (ALT) attracts top experts through lucrative stock options. Demand for its products remains stable and independent of economic cycles or GDP. High brand authority is sustained by expectations regarding research results, despite market volatility.

ALT altimmune.com Company Long-Term Liabilities (07/04/2022 - 10/28/2026)

Financial and market metric breakdowns for Altimmune Corp (ALT)

- price and consensus price forecast:
Price Performance Chart altimmune.com|ALT - Price Target Chart
- market capitalization data:
Market Valuation Altimmune|ALT - Enterprise Value
- book capitalization data:
Book Value per Share Altimmune|ALT - Company Net Assets|Market Value to Book Value altimmune.com|ALT - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Altimmune, Inc.|ALT - Long-Term Debt to Capital|Current Liabilities to Capital Altimmune Pharma|ALT - Company Total Debt|Debt to Book Capital Altimmune|ALT - Company Long-Term Debts|Company Short-Term Debts Altimmune
Fundamental company analysis:ALT (altimmune.com)
Original product of Altimmune

Altimmune, Inc. (ALT) relies on external contractors for drug development, making financial stability critically important. This indicator measures the aggregate of obligations with a maturity of more than one year, determining the long-term credit burden on capital. By analyzing the business's long-term borrowed funds, an investor assesses the company's ability to finance R&D without the risk of default. A stable trend confirms solvency and the validity of the asset's market value.

Who Altimmune, Inc. competes with

ascendispharma.com - Company Long-Term Loans and Borrowings|MDGL: Company Long-Term Debt|CORT - Company Long-Term Liabilities|RYTM: Company Long-Term Debts|Company Long-Term Debts Akero Corp|MTSR - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings MLTX|Company Long-Term Debt CRNX (Crinetics)|Company Long-Term Liabilities NewAmsterdam Pharma Company (NAMS)|SLNO: Company Long-Term Debts|FOLD - Long-Term Debt|Company Long-Term Liabilities 89bio, Inc. ETNB|AGIO - Amount of Long-Term Liabilities|GPCR: Company Long-Term Debts|MiMedx Group Inc (MDXG) - Company Long-Term Debts|Company Long-Term Debts Rezolute Corp|Company Long-Term Debt LXRX|MBX Biosciences Inc - Company Long-Term Debt|Long-Term Debt AARD (aardvarktherapeutics.com)|Company Long-Term Debt Sagimet Biosciences Inc. SGMT|Company Long-Term Debt BioAge Labs BIOA|Company Long-Term Debts BMEA (Biomea)|QNCX: Long-Term Debt Volume|Fractyl Health, Inc. - Company Long-Term Debt|VTVT (vTv Therapeutics) - Long-Term Debt Volume|Company Long-Term Debt ATPC|Company Long-Term Liabilities Pluri Inc|Company Long-Term Debts SYBX|Company Long-Term Debts LPCN (Lipocine Corporation)|Company Long-Term Debt Matinas BioPharma Holdings MTNB|SPRB - Company Long-Term Debt|Company Long-Term Liabilities Galecto GLTO|CTCX - Amount of Long-Term Liabilities|Lumos Pharma Corp - Company Long-Term Debts|ONVO (Organovo Corp) - Long-Term Debt Volume|Company Long-Term Debt RDUS